Meet Dr. Kelly Olino

Transcript

• 00:00Hi, my name is Kelly Olino.
• 00:03I'm a surgical oncologist,
• 00:04and at the Yale Cancer Center I treat
• 00:07patients with advanced skin cancers including
• 00:09Melanoma and Merkel cell carcinomas,
• 00:11and in addition to that I'm also an
• 00:14expert in the treatment of sarcoma.
• 00:16We're very fortunate that we really
• 00:18have a wonderful team approach from
• 00:21the minute patient picks up the phone,
• 00:23the person that they speak to on the
• 00:26other end really enables for us to have
• 00:29a seamless transition from their first.
• 00:31Appointment to the clinic visit.
• 00:34We have a multidisciplinary group of people
• 00:36and that includes surgeons like myself,
• 00:39plastic surgery,
• 00:40dermatology as well as medical
• 00:43oncology which really allows for
• 00:45both our skin cancer patients and
• 00:47our sarcoma patients to really have
• 00:50one stop access to all of their
• 00:52providers and for it to really be a
• 00:55very cohesive and seamless experience.
• 00:58Patients should always feel free
• 01:00to bring lists of questions.
• 01:02And concerns, because, again,
• 01:04there's so much information via
• 01:05in the Internet and social media.
• 01:07I'd much rather people come in with
• 01:10questions that they have and use me
• 01:12as almost their own personal medical
• 01:14encyclopedia and have every single
• 01:16one of those questions answered by the
• 01:18time that the clinic visit is over.
• 01:21And again to know that if they
• 01:23have additional questions,
• 01:24it's always OK to call again one
• 01:26of the main focus that we have,
• 01:29particularly with Melanoma,
• 01:30which was one of the early successes.
• 01:32In the treatment of immune therapy is
• 01:35to see how we can improve the platform,
• 01:38both in how we can minimize side
• 01:41effects while increasing the
• 01:42number of people who respond.
• 01:44For example,
• 01:45work that we've done and successfully
• 01:48taken from the laboratory now
• 01:50to the clinic has focused on
• 01:52a new target known as CD 40,
• 01:54and that actually led to us enabling
• 01:56to open a clinical trial which is
• 01:59now under active investigation,
• 02:01which really was the culmination.
• 02:03Of this seamless teamwork that
• 02:04I alluded to earlier,
• 02:06where patients have the benefit of us
• 02:08going from the bench to the bedside
• 02:10and then back to the bench to try
• 02:13and improve upon our treatments.